Covid-19 Vaccination Tracker

Latest news, statistics, daily rates & updates

Last updated 08 April, 2021 10:30 CEST

As the coronavirus vaccine rolls out across the globe, our world Covid-19 vaccine tracker will help you discover the latest Covid-19 updates and live tracking of vaccine development and administration

You can explore our data and find insights into Covid-19 vaccine clinical trials, country-level vaccination statistics, the impact of vaccination on infection and death rates, and all the latest news and information on the Covid-19 vaccination.

Number of vaccine doses administered globally

706,114,831

+7,119,130 reported yesterday

Number of fully vaccinated globally

149,355,054

+644,511 reported yesterday

Number of countries with a vaccination programme

114

+2 reported yesterday

Fully vaccinated global population

0.9%

+0% reported yesterday

Coronavirus vaccine roll out statistics by country

Public health authorities across the globe have been mobilising to deliver the biggest ever vaccination programme to battle Covid-19. How many people have received the Covid-19 vaccine? We bring you the latest Covid-19 vaccine numbers, including daily Covid-19 vaccine rates per country. Track worldwide Covid-19 vaccine rates with Pharmaceutical Technology and GlobalData.

Some countries have made a fast start with their vaccination efforts. By the end of January, Israel had successfully vaccinated 3 million people with the first dose. While the US may have had a slow start, President Biden has put the vaccination programme at the forefront of his first 100 days agenda. View the latest covid vaccine statistics below.

Country Doses Administered Doses per 1000 Fully Vaccinated Population (%) Vaccine being used in a country
World 706,114,831 93.0 2 %
US 171,476,655 524.1 18 % Pfizer/BioNTech, Moderna, Johnson&Johnson
Mainland China 145,390,000 104.4 0 % Sinopharm, Sinovac
India 90,198,673 66.7 1 % Covishield, Covaxin
United Kingdom 37,391,103 562.4 9 % Pfizer/BioNTech, Oxford/AstraZeneca
Brazil 27,663,734 132.1 3 % Oxford/AstraZeneca, Sinovac
Turkey 18,166,964 220.7 9 % Sinovac
Germany 16,251,310 196.0 6 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Indonesia 13,975,000 52.2 2 % Sinovac
Russia 13,433,272 92.1 4 % Sputnik V, EpiVacCorona
France 12,789,529 190.9 5 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Italy 11,738,824 194.3 6 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Chile 11,396,072 608.5 23 % Pfizer/BioNTech, Sinovac
Israel 10,164,254 1,144.1 55 % Pfizer/BioNTech, Moderna
Mexico 10,089,420 80.0 1 % Pfizer/BioNTech, Oxford/AstraZeneca, Sputnik V
Spain 9,357,847 200.3 6 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
United Arab Emirates 8,889,571 902.5 22 % Pfizer/BioNTech, Oxford/AstraZeneca, Sinopharm, Sputnik V
Morocco 8,448,106 234.5 11 % Oxford/AstraZeneca, Sinopharm
Poland 7,000,072 184.3 6 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Canada 6,991,804 188.7 2 % Pfizer/BioNTech, Moderna
Saudi Arabia 5,678,383 168.5 0 % Pfizer/BioNTech, Oxford/AstraZeneca
Bangladesh 5,568,703 34.5 0 % Oxford/AstraZeneca
Argentina 4,571,819 102.8 2 % Sinopharm, Sputnik V, Covishield
Hungary 3,686,031 377.3 11 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna, Sinopharm, Sputnik V
Romania 3,469,294 178.2 7 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Colombia 2,578,601 51.9 1 % Pfizer/BioNTech, Sinovac
Belgium 2,198,730 192.5 5 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Serbia 2,077,197 297.5 12 % Pfizer/BioNTech, Oxford/AstraZeneca, Sinopharm, Sputnik V
Netherlands 2,072,009 120.3 0 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Greece 2,003,644 186.8 6 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Portugal 1,969,036 191.5 6 % Pfizer/BioNTech, Moderna
Czechia 1,909,475 179.7 6 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Austria 1,872,531 211.7 6 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Sweden 1,856,666 182.3 5 % Pfizer/BioNTech, Oxford/AstraZeneca
Singapore 1,667,522 295.7 10 % Pfizer/BioNTech
Switzerland 1,604,838 188.4 7 % Pfizer/BioNTech, Moderna
Nepal 1,600,000 57.0 0 % Oxford/AstraZeneca
Japan 1,487,606 11.8 0 % Pfizer/BioNTech
Peru 1,230,904 38.5 2 % Sinopharm
Denmark 1,220,630 210.6 7 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Finland 1,120,653 203.1 2 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
South Korea 1,072,480 20.8 0 % Pfizer/BioNTech, Oxford/AstraZeneca,
Norway 1,070,018 201.4 5 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Slovakia 1,065,266 195.6 5 % Pfizer/BioNTech
Dominican Republic 1,000,000 94.1 0 % Oxford/AstraZeneca
Australia 996,145 39.9 0 % Pfizer/BioNTech, Oxford/AstraZeneca
Azerbaijan 982,291 98.8 4 % Sinovac
Qatar 961,555 345.7 0 % Pfizer/BioNTech
Ireland 940,883 193.9 6 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Sri Lanka 924,758 42.7 0 % Oxford/AstraZeneca
Bahrain 879,825 560.6 21 % Pfizer/BioNTech, Oxford/AstraZeneca, Sinopharm, Sputnik V
Uruguay 866,866 251.3 3 % Pfizer/BioNTech, Sinovac
Philippines 855,457 8.0 0 % Sinovac
Malaysia 830,036 25.8 1 % Pfizer/BioNTech
Pakistan 800,000 3.8 0 % Sinopharm, Sputnik V, Covishield
Kuwait 604,861 146.2 1 % Pfizer/BioNTech
Lithuania 596,505 213.8 6 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Bulgaria 533,453 75.9 2 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Costa Rica 504,930 101.0 4 % Pfizer/BioNTech
Mongolia 466,946 147.3 0 % Oxford/AstraZeneca
Croatia 427,387 104.5 2 % Pfizer/BioNTech
Jordan 409,203 41.1 1 % Pfizer/BioNTech, Sinopharm/Beijing
Slovenia 406,215 196.5 6 % Pfizer/BioNTech, Oxford/AstraZeneca
Panama 387,580 92.8 3 % Pfizer/BioNTech
Myanmar 380,000 7.1 0 % Oxford/AstraZeneca
Bolivia 378,455 33.3 1 % Sputnik V
Rwanda 348,926 28.4 0 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Ukraine 334,578 7.5 0 % Oxford/AstraZeneca
Thailand 323,989 4.7 0 % Oxford/AstraZeneca, Sinovac
Estonia 308,633 233.7 5 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Senegal 308,318 19.5 0 % Sinopharm
South Africa 278,909 4.8 0 % Johnson&Johnson
Maldives 270,854 525.2 2 % Oxford/AstraZeneca
Cambodia 248,150 15.3 0 % Sinopharm
Lebanon 244,772 35.7 1 % Pfizer/BioNTech
Malta 227,606 470.7 13 % Pfizer/BioNTech
Albania 221,588 77.3 0 % Pfizer/BioNTech
Zimbabwe 179,417 12.4 0 % Sinopharm
Latvia 163,844 85.1 1 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Oman 158,752 32.9 0 % Pfizer/BioNTech, Oxford/AstraZeneca
Cyprus 148,299 117.1 3 % Pfizer/BioNTech
Ecuador 139,359 8.2 0 % Pfizer/BioNTech
El Salvador 133,330 20.8 0 % Oxford/AstraZeneca
Iran 124,193 1.5 0 % Sputnik V
Guatemala 119,558 6.9 0 % Moderna
Luxembourg 112,764 185.6 4 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Kazakhstan 109,995 6.0 0 % Sputnik V
Seychelles 103,968 1,074.5 41 % Oxford/AstraZeneca, Sinopharm
Algeria 91,349 2.2 0 % Sputnik V
New Zealand 90,286 18.5 0 % Pfizer/BioNTech
Iceland 79,726 225.5 8 % Pfizer/BioNTech, Oxford/AstraZeneca, Moderna
Belarus 66,618 7.0 0 % Sputnik V
Barbados 63,738 222.4 0 % Oxford/AstraZeneca
Gibraltar 60,907 1,806.4 85 % Pfizer/BioNTech
Cayman Islands 53,638 835.8 21 % Pfizer/BioNTech
Honduras 52,772 5.5 0 % Oxford/AstraZeneca, Moderna
Moldova 51,574 14.5 0 % Oxford/AstraZeneca
Paraguay 45,494 6.5 0 % Sputnik V
Guyana 40,468 52.0 0 % Oxford/AstraZeneca
Montenegro 34,335 55.2 1 % Sinopharm/Beijing, Sputnik V
Bermuda 27,727 433.5 16 % Pfizer/BioNTech
Saint Lucia 22,554 124.0 0 % Oxford/AstraZeneca
Belize 22,067 57.6 0 % Oxford/AstraZeneca
Dominica 16,058 224.2 0 % Oxford/AstraZeneca
Monaco 15,612 403.6 19 % Pfizer/BioNTech
San Marino 13,475 398.9 14 % Sputnik V
Andorra 13,148 170.7 2 % Pfizer/BioNTech
Turks and Caicos Islands 12,935 343.4 0 % Pfizer/BioNTech
Grenada 9,821 88.1 0 % Oxford/AstraZeneca
Liechtenstein 6,503 171.5 6 % Pfizer/BioNTech, Moderna
Anguilla 5,348 356.5 0 % Oxford/AstraZeneca
Greenland 5,130 91.6 2 % Pfizer/BioNTech
Mauritius 3,843 3.0 0 % Oxford/AstraZeneca
Egypt 1,315 0.0 0 % Sinopharm
Trinidad and Tobago 991 0.7 0 % Oxford/AstraZeneca

World map of vaccinations – total doses and fully vaccinated

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine numbers as they happen each day.

Total doses tracks the number of vaccine doses applied, whether they be the first or second of the two dose treatments or the one dose vaccine. Fully vaccinated captures the combined number of people to have received either both shots of a two-stage vaccine or the one-shot vaccine. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

The first ever dose of Covid-19 vaccine was administered in the UK in December 2020, and the global vaccination effort has fast expanded with most countries beginning to start their vaccination programmes.

However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out. View the Covid-19 vaccination world map below.

GlobalData brings you a map of total worldwide Covid-19 vaccination rates per country, which lets you track Covid-19 vaccine first dose and second dose numbers as they happen each day. See which countries are administering most Covid-19 vaccines and where efforts are falling short.

With the worldwide first dose vaccination administered in the UK in December 2020, the global Covid-19 vaccination effort has fast expanded with most countries beginning to start their vaccination programmes. However, supply issues which have hit the EU in January and vaccine poverty fears in the developing world still pose challenges for the worldwide Covid-19 vaccine roll-out.

Global Covid-19 vaccinations

This Covid-19 vaccination chart shows a steadily growing Covid-19 vaccination rate globally since January 2021, the first full month of the global Covid-19 vaccination drive. For more details also see GlobalData’s intelligence on Covid-19 vaccinations per country.

Country-level Covid-19 vaccination

With Israel having a head start with Covid-19 vaccine numbers, many countries are stepping up their effort to battle new cases and death rates with fast Covid-19 vaccine roll-outs.

Vaccines administered

Vaccine doses per 1,000 people

Fully vaccinated population

Leading vaccine candidates and current status

At the start of February nine approved Covid-19 vaccines were being used globally to fight the rising global death rate from Covid-19. The Janssen vaccine is likely to achieve imminent approval and there are almost 50 other Covid-19 vaccines still in development. Some might never progress to regulatory approval, but with new variants of Covid-19 spreading fast the race for the most effective and affordable Covid-19 vaccine is still on. Follow GlobalData’s tracker on Covid-19 vaccine initiatives and Covid-19 vaccine trials here:

Progress: Trial Results expected Awaiting approval Available to public
Trial size Doses requierd Storage temperature Efficacy Number of countries approved

Pfizer/BioNTech 46,331 2 -60°C to -90°C 95% 18

mRNA vaccine, first to demonstrate positive Phase 3 results. Impressive efficacy of 95% in prevention of Covid-19, with a single drawback of requiring unusually cold (-70 degrees F) conditions for storage and transportation.

Trial Start Date - 29 April 2020
Result Publication Date - 18 November 2020
1 Mar,2021: Complete Approval given by Denmark
14 Feb,2021: Complete Approval given by Japan
10 Feb, 2021: Emergency Use Authorization given by New Zealand
25 Jan, 2021: Complete Approval given by Australia
25 Jan, 2021: Emergency Use Authorization given by Hong Kong
6 Jan, 2021: Emergency Use Authorization given by Colombia
21 Dec, 2020: Complete Approval given by EU
21 Dec, 2020: Emergency Use Authorization given by Qatar
19 Dec, 2020: Complete Approval given by Switzerland
16 Dec, 2020: Emergency Use Authorization given by Panama
14 Dec, 2020: Emergency Use Authorization given by Singapore
13 Dec, 2020: Emergency Use Authorization given by Kuwait
12 Dec, 2020: Emergency Use Authorization given by Mexico
11 Dec, 2020: Emergency Use Authorization given by US
10 Dec, 2020: Emergency Use Authorization given by Saudia Arabia
9 Dec, 2020: Emergency Use Authorization given by Canada
4 Dec, 2020: Emergency Use Authorization given by Bahrain
2 Dec, 2020: Emergency Use Authorization given by UK
Today

Moderna 30,420 2 -20°C 94.5% 8

Like Pfizer/BioNTech’s offering, is an mRNA vaccine with a nearly identical 95% efficacy for prevention of Covid-19. Also requires freezing temperatures but does not require ultra-low temperatures as Pfizer/BioNTech’s vaccine does.

Trial Start Date - 27 July 2020
Result Publication Date - 16 November 2020
11 Feb, 2021: Emergency Use Authorization given by Qatar
3 Feb, 2021: Emergency Use Authorization given by Singapore
12 Jan, 2021: Emergency Use Authorization given by Switzerland
8 Jan, 2021: Emergency Use Authorization given by UK
6 Jan, 2021: Complete Approval given by EU
4 Jan, 2021: Authorization to import given by Israel
23 Dec, 2020: Emergency Use Authorization given by Canada
18 Dec, 2020: Emergency Use Authorization given by US
Today

AstraZeneca Plc 24,820 2 2 - 8°C 70.4 28

Adenoviral vaccine which has produced mixed results depending on region, vaccine dosing regimen, and schedule. While overall efficacy may be lower than some competitors, protections against hospitalization and death is strong.

Trial Start Date - 28 May 2020
Result Publication Date - 08 December 2020
2 Mar, 2021: Emergency Use Authorization given by Malaysia
26 Feb, 2021: Emergency Use Authorization given by Canada
18 Feb, 2021: Emergency Use Authorization given by Saudi Arabia
17 Feb, 2021: Emergency Use Authorization given by Iran
16 Feb, 2021: Emergency Use Authorization given by Australia
15 Feb, 2021: Emergency Use Listing (EUL) given by WHO
6 Feb, 2021: Complete Approval given by Spain
5 Feb, 2021: Emergency Use Authorization given by Greece
2 Feb, 2021: Complete Approval given by France
2 Feb, 2021: Complete Approval given by Sweden
1 Feb, 2021: Emergency Use Authorization given by Vietnam
31 Jan, 2021: Emergency Use Authorization given by Kuwait
30 Jan, 2021: Complete Approval given by Italy
29 Jan, 2021: Complete Approval given by EU
29 Jan, 2021: Emergency Use Authorization given by Philippines
23 Jan, 2021: Emergency Use Authorization given by South Africa
21 Jan, 2021: Emergency Use Authorization given by Thailand
21 Jan, 2021: Emergency Use Authorization given by Hungary
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Brazil
17 Jan, 2021: Emergency Use Authorization given by Pakistan
6 Jan, 2021: Emergency Use Authorization given by India
6 Jan, 2021: Emergency Use Authorization given by Argentina
6 Jan, 2021: Emergency Use Authorization given by Dominican Republic
6 Jan, 2021: Emergency Use Authorization given by El Salvador
6 Jan, 2021: Emergency Use Authorization given by Mexico
6 Jan, 2021: Emergency Use Authorization given by Morocco
30 Dec, 2020: Emergency Use Authorization given by UK
Today

Novavax Inc 15,203 2 2 - 8°C 89.3% 0

Uses virus-like particles (VLPs) produced in insect cells and demonstrated nearly 90% efficacy against Covid-19 in studies conducted in the UK.

Trial Start Date - 28 September 2020
Result Publication Date - 28 January 2021
Today

Johnson & Johnson 44,325 1 2 - 8°C 66% 3

Adenoviral vaccine able to confer nearly 70% protection against all Covid-19 with a single dose. Like AstraZeneca’s vaccine, overall protection is not the highest, but offers near-complete protection against hospitalization and death. Also being tested as a two-dose regimen.

Trial Start Date - 07 September 2020
Result Publication Date - 29 January 2021
5 Mar, 2021: Emergency Use Authorization given by Canada
27 Feb, 2021: Emergency Use Authorization given by the US
25 Feb, 2021: Emergency Use Authorization given by the US
https://www.aljazeera.com/news/2021/2/17/south-africa-begins-vaccine-rollout-through-observational-study
Today

Gamaleya 33,758 2 2 - 8°C 91.4% 38

Developed by Russia, uses two different adenoviruses, one for each of two doses, as part of a heterologous vaccination plan. Has shown excellent efficacy of just over 90% in preventing all Covid-19.

Early Approval - 12 August 2020
Trial Start Date - 07 September 2020
Result Publication Date - 14 December 2020
7 Mar, 2021: Emergency Use Authorization given by Macedonia
4 Mar, 2021: Emergency Use Authorization given by Sri Lanka
3 Mar, 2021: Emergency Use Authorization given by Angola
3 Mar, 2021: Emergency Use Authorization given by Djibouti
3 Mar, 2021: Emergency Use Authorization given by Republic of the Congo
1 Mar, 2021: Emergency Use Authorization given by Slovakia
25 Feb, 2021: Emergency Use Authorization given by Guatemala
24 Feb, 2021: Emergency Use Authorization given by Egypt
24 Feb, 2021: Emergency Use Authorization given by Honduras
20 Feb, 2021: Emergency Use Authorization given by Ghana
19 Feb, 2021: Emergency Use Authorization given by San Marino
17 Feb, 2021: Emergency Use Authorization given by Gabon
17 Feb, 2021: Emergency Use Authorization given by Uzbekistan
12 Feb, 2021: Emergency Use Authorization given by Montenegro
10 Feb, 2021: Emergency Use Authorization given by Bahrain
9 Feb, 2021: Emergency Use Authorization given by Mongolia
9 Feb, 2021: Emergency Use Authorization given by Pakistan
6 Feb, 2021: Emergency Use Authorization given by Myanmar
6 Feb, 2021: Emergency Use Authorization given by Bosnia and Herzegovina
5 Feb, 2021: Emergency Use Authorization given by Lebanon
3 Feb, 2021: Emergency Use Authorization given by Mexico
3 Feb, 2021: Emergency Use Authorization given by Nicaragua
1 Feb, 2021: Emergency Use Authorization given by Armenia
30 Jan, 2021: Emergency Use Authorization given by Tunisia
29 Jan, 2021: Emergency Use Authorization given by Republic of Guinea
26 Jan, 2021: Emergency Use Authorization given by Iran
21 Jan, 2021: Emergency Use Authorization given by Hungary
21 Jan, 2021: Emergency Use Authorization given by UAE
18 Jan, 2021: Emergency Use Authorization given by Turkmenistan
15 Jan, 2021: Emergency Use Authorization given by Paraguay
13 Jan, 2021: Emergency Use Authorization given by Venezuela
11 Jan, 2021: Emergency Use Authorization given by Palestine
10 Jan, 2021: Emergency Use Authorization given by Algeria
6 Jan, 2021: Emergency Use Authorization given by Bolivia
28 Dec, 2020: Approved by Russia for population aged 60 years and above
23 Dec, 2020: Emergency Use Authorization given by Argentina
21 Dec, 2020: Emergency Use Authorization given by Belarus
12 Aug, 2020: Complete Approval given by Russia
Today

Sinovac Biotech 29,608 2 2 - 8°C 50.65% 12

Vaccine from China, one of few vaccines using inactivated SARS-CoV-2 viruses which is a much more conventional vaccine technology than others which have demonstrated positive Phase III data.

Early Approval - 11 January 2021
Trial Start Date - 21 July 2020
Result Publication Date - 05 February 2021
2 Mar, 2021: Emergency Use Authorization given by Malaysia
22 Feb, 2021: Emergency Use Authorization given by Philippines
22 Feb, 2021: Emergency Use Authorization given by Thailand
13 Feb, 2021: Emergency Use Authorization given by Cambodia
11 Feb, 2021: Emergency Use Authorization given by Mexico
8 Feb, 2021: Emergency Use Authorization given by China
5 Feb, 2021: Emergency Use Authorization given by Colombia
21 Jan, 2021: Emergency Use Authorization given by Chile
18 Jan, 2021: Emergency Use Authorization given by Brazil
13 Jan, 2021: Emergency Use Authorization given by Turkey
13 Jan, 2021: Emergency Use Authorization given by Turkey
11 Jan, 2021: Emergency Use Authorization given by Indonesia
Today

Sinopharm 60,000+ 2 2 - 8°C 86.0% 14

The second inactivated vaccine, also being developed by China, has shown mixed results in Brazil, where initial efficacy was 86% based on data from the UAE, but efficacy data from Brazil were significantly lower at only 50%.

Early Approval - 12 October 2020
Trial Start Date - 16 July 2020
Result Publication Date - 10 December 2020
26 Feb, 2021: Emergency Use Authorization given by Guyana
22 Feb, 2021: Emergency Use Authorization given by Argentina
4 Feb, 2021: Emergency Use Authorization given by Cambodia
29 Jan, 2021: Emergency Use Authorization given by Hungary
27 Jan, 2021: Emergency Use Authorization given by Peru
24 Jan, 2021: Emergency Use Authorization given by Morocco
19 Jan, 2021: Emergency Use Authorization given by Pakistan
19 Jan, 2021: Emergency Use Authorization given by Iraq
18 Jan, 2021: Emergency Use Authorization given by Republic of Serbia
9 Jan, 2021: Emergency Use Authorization given by Jordan
4 Jan, 2021: Emergency Use Authorization given by Egypt
2 Jan, 2021: Emergency Use Authorization given by China
14 Dec, 2020: Emergency Use Authorization given by Bahrain
10 Dec, 2020: Complete Approval given by UAE
Today

CanSino Biologics 40,000 1 2 - 8°C 65.7% 3

Like Johnson & Johnson’s vaccine, this vaccine from China showed just under 70% efficacy in preventing all Covid-19 and 90% efficacy in preventing severe Covid-19 with just a single dose.

12 Feb, 2021: Emergency Use Authorization given by Pakistan
11 Feb, 2021: Emergency Use Authorization given by Mexico
25 Jun, 2020: Military Use Authorization given by China
Trial Start Date - 15 September 2020
Today

Covid-19 vaccine clinical trials by region

Covid-19 vaccine clinical trials by trial phase

Covid-19 vaccine clinical trials by trial status

Covid-19 - The race to herd immunity

According to the World Health Organization (WHO), "Herd Immunity, also known as population immunity, is the indirect protection from an infectious disease that happens when a population is immune either through vaccination or immunity developed through previous infection."

Herd immunity against Covid-19 has been widely debated over the past months, however WHO has admitted, "we do not have a clear understanding of the herd immunity level for Covid-19."

So, what is the herd immunity percentage for Covid-19?

In the context of Covid-19, herd immunity level is 60-70%,but could be higher if the new variants of the virus are more contagious.

The assumption should always be higher rather than lower with some recent research suggesting the number of the population that needed to be vaccinated ranged from 69-93%.

Race to herd immunity (Top 20 countries by vaccination rate)

Race to herd immunity (Leading economies)